Igenerix Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 15-05-2024
- Paid Up Capital ₹ 0.10 M
as on 15-05-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -11.11%
(FY 2021)
- Profit -56.35%
(FY 2021)
- Ebitda -74.23%
(FY 2021)
- Net Worth 7.47%
(FY 2021)
- Total Assets -9.40%
(FY 2021)
About Igenerix Pharma
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jyoti Rawal and Arvinder Sodhi serve as directors at the Company.
- CIN/LLPIN
U73200UP2008PTC170816
- Company No.
045183
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Feb 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Igenerix Pharma Private Limited offer?
Igenerix Pharma Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Services, Industrial Chemicals & Supplies, Agro Chemicals, Medical Consultants & Clinics, Medical Consultancy Services, Warehousing Management Services, Procurement Services.
Who are the key members and board of directors at Igenerix Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyoti Rawal  | Director | 03-Nov-2011 | Current |
| Arvinder Sodhi | Director | 05-Feb-2008 | Current |
Financial Performance and Corporate Structure Insights of Igenerix Pharma.
Igenerix Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 11.11% decrease. The company also saw a substantial fall in profitability, with a 56.35% decrease in profit. The company's net worth moved up by a moderate rise of 7.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Igenerix Pharma?
In 2021, Igenerix Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hampton Pharma Private LimitedActive 16 years 10 monthsJyoti Rawal and Arvinder Sodhi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Igenerix Pharma?
Unlock and access historical data on people associated with Igenerix Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Igenerix Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Igenerix Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
